Abstraction Health

Berberine — Research Evidence

Source: PubMed / NCBI · human studies preferred · ranked by evidence qualityLast analyzed: May 24, 2026
🟡Moderate Evidence
21 studies·6 RCTs·12 reviews

The summary below was generated by an AI system (Claude) based on the studies listed. It is a synthesis tool, not a clinical opinion. Read individual studies for full context.

Berberine is a plant alkaloid with a long history in traditional Chinese and Ayurvedic medicine, and the modern research base — while growing — presents a nuanced picture. Evidence from multiple RCTs, systematic reviews, and a meta-analysis suggests that berberine has real, measurable effects on blood glucose, lipid profiles, and certain metabolic markers. However, of 160 expert claims reviewed against this literature, fewer than 5% were fully supported, and more than half had insufficient evidence, indicating that the popular narrative around berberine substantially outpaces what the science currently confirms.

The most consistent finding across the provided literature is berberine's ability to lower blood glucose in people with type 2 diabetes or insulin resistance. RCTs examining berberine alone and in combination with probiotics or cinnamon in type 2 diabetes populations show meaningful reductions in fasting glucose and HbA1c. A systematic review and meta-analysis also found favorable effects on obesity-related parameters, inflammation markers, and liver function enzymes. Multiple reviews note lipid-lowering properties — particularly LDD cholesterol and triglyceride reductions — positioning berberine as a potential nutraceutical option within cardiovascular risk management. More limited evidence from a single pre-post study suggests benefit in PCOS-related hormonal and metabolic parameters, though this design is weak for causal inference.

Important caveats temper these findings. Most studies are short-term, involve relatively small samples, and focus on populations with existing metabolic dysfunction, so effects in generally healthy adults remain unclear. Bioavailability is a recognized challenge with standard berberine formulations, and at least one study used a phospholipid-complexed form, making cross-study comparisons difficult. Safety reviews flag potential cardiovascular concerns associated with supplement use broadly, and herb-drug interactions — including with immunosuppressants like tacrolimus — are noted in the literature. Long-term safety data in humans remain limited, and the optimal dose, duration, and formulation for most applications have not been established.

Key findings

  • Multiple RCTs in type 2 diabetes populations demonstrate clinically meaningful reductions in fasting blood glucose and HbA1c with berberine supplementation.
  • A systematic review and meta-analysis found berberine favorably affects obesity parameters, inflammatory markers, and liver enzyme levels.
  • Several reviews and RCTs support modest lipid-lowering effects, particularly reductions in LDL cholesterol and triglycerides.
  • Combination regimens (berberine plus probiotics or cinnamon) show additive metabolic benefits in some RCTs, though evidence remains preliminary.
  • One pre-post study in PCOS patients reported improvements in insulin sensitivity and hormonal markers, but this design cannot establish causation.

Evidence gaps

  • ?Nearly all studies focus on people with existing metabolic conditions (type 2 diabetes, obesity, PCOS); effects in healthy, non-diabetic adults are largely unknown.
  • ?Long-term safety and efficacy data beyond short trial windows are absent, and optimal dosing and formulation (standard vs. phospholipid-complexed berberine) have not been established.
  • ?Potential drug interactions — including with immunosuppressants and possibly other medications metabolized by CYP enzymes — are flagged in reviews but not systematically characterized in clinical populations.

Safety summary

Berberine is generally described as tolerable in short-term trials, with gastrointestinal side effects being the most commonly reported issue. However, cardiovascular safety signals associated with supplement use and clinically relevant herb-drug interactions (including with tacrolimus) are noted in the literature, warranting caution — particularly in individuals on prescription medications.

Studies (21)

The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials.

Clinical nutrition ESPEN · 2020 · Asbaghi O et al.
Meta-Analysis🟢
Key finding

The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials.

COI: Declaration of Competing Interest All the authors declared that they have no conflicts of interest.
PMID: 32690176DOI: 10.1016/j.clnesp.2020.04.010
View on PubMed

The effect of berberine supplementation on obesity indices: A dose- response meta-analysis and systematic review of randomized controlled trials.

Complementary therapies in clinical practice · 2020 · Xiong P et al.
Meta-Analysis🟢
Key finding

The effect of berberine supplementation on obesity indices: A dose- response meta-analysis and systematic review of randomized controlled trials.

Funded by: Industry (inferred from affiliations)
COI: Declaration of competing interest The authors declare no conflict of interest.
PMID: 32379652DOI: 10.1016/j.ctcp.2020.101113
View on PubMed

Effects berberine-silymarin on liver enzymes: A systematic review and meta-analysis of randomized controlled trials.

Clinical nutrition ESPEN · 2022 · Mohtashaminia F et al.
Meta-Analysis🟢
Key finding

Effects berberine-silymarin on liver enzymes: A systematic review and meta-analysis of randomized controlled trials.

COI: Declaration of competing interest The authors declared no conflicts of interest.
PMID: 35623810DOI: 10.1016/j.clnesp.2022.01.037
View on PubMed

Efficacy of berberine in patients with type 2 diabetes mellitus.

Metabolism: clinical and experimental · 2008 · Yin J et al.
RCT🟡
Key finding

Efficacy of berberine in patients with type 2 diabetes mellitus.

Funded by: NCCIH NIH HHS, NIDDK NIH HHS
PMID: 18442638DOI: 10.1016/j.metabol.2008.01.013
View on PubMed

Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study).

Nature communications · 2020 · Zhang Y et al.
RCT🟡
Key finding

Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study).

COI: The authors declare no competing interests.
PMID: 33024120DOI: 10.1038/s41467-020-18414-8
View on PubMed

Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study.

Gut microbes · 2022 · Wang S et al.
RCT🟡
Key finding

Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study.

COI: No potential conflict of interest was reported by the authors.
PMID: 34923903DOI: 10.1080/19490976.2021.2003176
View on PubMed

Berberine Phospholipid Is an Effective Insulin Sensitizer and Improves Metabolic and Hormonal Disorders in Women with Polycystic Ovary Syndrome: A One-Group Pretest-Post-Test Explanatory Study.

Nutrients · 2021 · Rondanelli M et al.
RCT🟡
Key finding

Berberine Phospholipid Is an Effective Insulin Sensitizer and Improves Metabolic and Hormonal Disorders in Women with Polycystic Ovary Syndrome: A One-Group Pretest-Post-Test Explanatory Study.

COI: The authors declare no conflict of interest.
PMID: 34684666DOI: 10.3390/nu13103665
View on PubMed

The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial.

European journal of nutrition · 2025 · Mansour A et al.
RCT🟡
Key finding

The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial.

Funded by: National Institute for Medical Research Development
COI: Declarations. Consent for publication: Not applicable. Competing interests: It should be emphasized that Dr. Vahid Mofid is an employee of Pajoohesh Gostran Taghzie asan® Company. Other authors have not conflicts of interest or financial ties to disclose.
PMID: 39998703DOI: 10.1007/s00394-025-03618-9
View on PubMed

Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes.

Physiological reports · 2024 · Nikseresht M et al.
RCT🟡
Key finding

Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes.

COI: The authors declare that no conflict of interest would prejudice their impartiality.
PMID: 39107107DOI: 10.14814/phy2.16146
View on PubMed

Cardiovascular toxicity associated with supplement use.

Clinical toxicology (Philadelphia, Pa.) · 2025 · Corcoran J
Review🟡
Key finding

Cardiovascular toxicity associated with supplement use.

PMID: 40960841DOI: 10.1080/15563650.2025.2550983
View on PubMed

Dietary supplements: clinical cholesterol-lowering efficacy and potential mechanisms of action.

International journal of food sciences and nutrition · 2024 · Ge Q et al.
Review🟡
Key finding

Dietary supplements: clinical cholesterol-lowering efficacy and potential mechanisms of action.

Funded by: Industry (inferred from affiliations)
PMID: 38659110DOI: 10.1080/09637486.2024.2342301
View on PubMed

A network meta-analysis on the comparative effect of nutraceuticals on lipid profile in adults.

Pharmacological research · 2022 · Osadnik T et al.
Review🟡
Key finding

A network meta-analysis on the comparative effect of nutraceuticals on lipid profile in adults.

Funded by: Industry (inferred from affiliations)
PMID: 35988871DOI: 10.1016/j.phrs.2022.106402
View on PubMed

Berberine a traditional Chinese drug repurposing: Its actions in inflammation-associated ulcerative colitis and cancer therapy.

Frontiers in immunology · 2022 · Zhu C et al.
Review🟡
Key finding

Berberine a traditional Chinese drug repurposing: Its actions in inflammation-associated ulcerative colitis and cancer therapy.

COI: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
PMID: 36561763DOI: 10.3389/fimmu.2022.1083788
View on PubMed

Nutraceutical activation of Sirt1: a review.

Open heart · 2022 · DiNicolantonio JJ et al.
Review🟡
Key finding

Nutraceutical activation of Sirt1: a review.

COI: Competing interests: JJD is affiliated with companies that sell supplements. MM and JO own companies that sell supplements.
PMID: 36522127DOI: 10.1136/openhrt-2022-002171
View on PubMed

Tacrolimus and herbs interactions: a review.

Die Pharmazie · 2021 · Abushammala I
Review🟡
Key finding

Tacrolimus and herbs interactions: a review.

Funded by: Industry (inferred from affiliations)
PMID: 34620272DOI: 10.1691/ph.2021.1684
View on PubMed

Nutraceutical approaches to metabolic syndrome.

Annals of medicine · 2017 · Sirtori CR et al.
Review🟡
Key finding

Nutraceutical approaches to metabolic syndrome.

PMID: 28786719DOI: 10.1080/07853890.2017.1366042
View on PubMed

A Clinicians Guide to Recommending Common Cholesterol-Lowering Dietary Supplements.

American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024 · Backes JM et al.
Review🟡
Key finding

A Clinicians Guide to Recommending Common Cholesterol-Lowering Dietary Supplements.

Funded by: Industry (inferred from affiliations)
PMID: 39297910DOI: 10.1007/s40256-024-00681-1
View on PubMed

Hypolipaemic nutraceutics: red yeast rice and Armolipid, berberine and bergamot.

Annals of agricultural and environmental medicine : AAEM · 2021 · Kłosiewicz-Latoszek L et al.
Review🟡
Key finding

Hypolipaemic nutraceutics: red yeast rice and Armolipid, berberine and bergamot.

PMID: 33775071DOI: 10.26444/aaem/130629
View on PubMed

Berberine and lycopene as alternative or add-on therapy to metformin and statins, a review.

European journal of pharmacology · 2021 · Hedayati N et al.
Review🟡
Key finding

Berberine and lycopene as alternative or add-on therapy to metformin and statins, a review.

Funded by: Industry (inferred from affiliations)
PMID: 34801530DOI: 10.1016/j.ejphar.2021.174590
View on PubMed

Nutraceutical Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Path to Liver Health.

Nutrients · 2025 · Vrentzos E et al.
Review🟡
Key finding

Nutraceutical Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Path to Liver Health.

COI: The authors declare no conflicts of interest.
PMID: 40431398DOI: 10.3390/nu17101657
View on PubMed